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Abstract
Human aldo-keto reductase 1B15 (AKR1B15) is a newly discovered enzyme which shares
92% amino acid sequence identity with AKR1B10. While AKR1B10 is a well characterized
enzyme with high retinaldehyde reductase activity, involved in the development of several
cancer types, the enzymatic activity and physiological role of AKR1B15 are still poorly
known. Here, the purified recombinant enzyme has been subjected to substrate specificity
characterization, kinetic analysis and inhibitor screening, combined with structural model-
ing. AKR1B15 is active towards a variety of carbonyl substrates, including retinoids, with
lower kcat and Km values than AKR1B10. In contrast to AKR1B10, which strongly prefers all-
trans-retinaldehyde, AKR1B15 exhibits superior catalytic efficiency with 9-cis-retinalde-
hyde, the best substrate found for this enzyme. With ketone and dicarbonyl substrates,
AKR1B15 also shows higher catalytic activity than AKR1B10. Several typical AKR inhibitors
do not significantly affect AKR1B15 activity. Amino acid substitutions clustered in loops A
and C result in a smaller, more hydrophobic and more rigid active site in AKR1B15 com-
pared with the AKR1B10 pocket, consistent with distinct substrate specificity and narrower
inhibitor selectivity for AKR1B15.
Introduction
Members of the aldo-keto reductase (AKR) superfamily share an (α/β)8 barrel fold and are
mostly monomeric (~35 kDa) NAD(P)H-dependent enzymes catalyzing the reduction of a
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wide variety of endogenous carbonyl compounds such as carbohydrates, lipid aldehydes, pros-
taglandins, steroids and retinoids [1,2]. Several AKR enzymes act in phase-I drug metabolism
by transforming some xenobiotics, are induced by nuclear factor erythroid 2-related factor 2
(Nrf2) under oxidative stress, and are involved in cancer chemoresistance [3,4]. In the human
genome, fifteen AKR genes have been described which belong to three different gene families
(AKR1, AKR6 and AKR7). The AKR1B subfamily gene cluster, located in chromosome 7q33-
35, includes the AKR1B1, AKR1B10 and AKR1B15 genes. A syntenic gene cluster with four loci
has been described in rodent species, although gene orthologs can only be unambiguously
assigned for AKR1B1 [5,6].
The most studied enzyme of the AKR1B subfamily is AKR1B1 or aldose reductase, which
reduces glucose to sorbitol under hyperglycemia and has been involved in the secondary com-
plications of diabetic disease [7]. Another member, AKR1B10, is normally expressed in adrenal
gland and small intestine, and induced in several types of cancer, such as non-small cell lung
carcinoma and hepatoma [3]. Both enzymes have been proposed as promising oncogenic tar-
gets [8,9] and for this reason, along with the role of AKR1B1 in diabetic disease, they have been
the subject of many studies in the search of selective and potent inhibitors [10–15]. Unlike
other members of the subfamily, AKR1B10 is highly active in the reduction of all-trans-retinal-
dehyde [5]. The third gene in the AKR1B cluster, AKR1B15, has been predicted in the last
decade as a result of high-throughput sequencing and annotation projects, i.e. human genome.
Recently, AKR1B15 has been demonstrated to be a functional gene with low expression
restricted to placenta, testes and adipose tissues. The AKR1B15 gene undergoes alternative
splicing giving rise to two protein isoforms, designated as AKR1B15.1 and AKR1B15.2. The
former is a 316-amino acid protein encoded by AKR1B15-201 mRNA (Ensembl database) and
showing 92% amino acid sequence identity with AKR1B10, whereas AKR1B15.2 (AKR1B15-
001, Ensembl) has a longer N-terminus not homologous to other AKRs, and does not exhibit
enzymatic activity or nucleotide binding [16]. AKR1B15.1 (henceforth referred to in this man-
uscript as AKR1B15 for brevity) is localized in the mitochondrial fraction and the recombinant
protein was purified and characterized, showing limited in vitro activity with steroids and acet-
oacetyl-CoA [16]. Previously, AKR1B15.1 had been expressed in the insoluble fraction of
mammalian cells, showing low activity with D,L-glyceraldehyde and 4-nitrobenzaldehyde [6].
Similarly to AKR1B10, the AKR1B15 gene was found to be up-regulated in the airway epithe-
lium by smoking [17] and by exposure to sulforaphane, a known activator of the antioxidant
response [18]. Interest in the AKR1B15 gene has risen lately because some allelic variants have
been linked to a mitochondrial oxidative phosphorylation disease [19], serous ovarian carci-
noma [20] and increased longevity [21].
With the aim of further characterizing the enzymatic function of AKR1B15, we have per-
formed enzyme kinetics of the purified recombinant protein with retinaldehyde isomers and
other typical carbonyl substrates of AKR1B10. We have also conducted a screening against
potential inhibitors using compounds previously described for AKR1B1 or AKR1B10. Finally,
based on the crystallographic structure of the AKR1B10 complex with NADP+ and tolrestat,
we have constructed a model of the AKR1B15 active-site pocket.
Materials and Methods
Bacterial strains, plasmids and reagents
E. coli BL21(DE3) strain was obtained from Novagen, while plasmids pBB540 and pBB542
(containing the chaperone-coding genes grpE, clpB and dnaK, dnaJ, groESL, respectively), were
a kind gift from Dr. A. de Marco [22]. The pET-28a vector containing the cDNA coding for
isoform 2 of AKR1B15 (UniProt ID: C9JRZ8-2) had been described by Salabei et al. [6].
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Tolrestat and sorbinil were generously provided by Prof. T.G. Flynn and Pfizer, respectively,
whereas JF0064 (2,2’,3,3’,5,5’,6,6’-octafluoro-4,4’-biphenyldiol) was obtained from Sigma-
Aldrich. Trans-2-hexenal and 4-hydroxy-2-nonenal were commercially obtained from Cay-
man Chemical. All other reagents, including substrates, were purchased from Sigma-Aldrich
unless otherwise indicated.
Protein expression and purification
E. coli BL21(DE3) strain transformed with pET-28a/AKR1B15 was grown in 1 L of 2xYT
medium in the presence of 33 μg/mL kanamycin, while E. coli BL21(DE3) containing pBB540,
pBB542 and pET-28a/AKR1B15 was grown in 6 L of M9 minimal medium supplemented with
20% glucose as a carbon source, in the presence of 34 μg/mL chloramphenicol, 50 μg/mL spec-
tinomycin and 33 μg/mL kanamycin. Protein expression was then induced by the addition of 1
mM IPTG (Apollo Scientific) and cells were further incubated for 4 h at 22°C. Cells were then
pelleted and resuspended in ice-cold TBI buffer (150 mMNaCl, 10 mM Tris-HCl, 5 mM imid-
azole, pH 8.0) containing 1% (v/v) Triton X-100. In the case of the non-chaperone-expressing
E. coli BL21(DE3) strain, the TBI buffer also contained 1% (w/v) sarkosyl. The protein was
purified using a His-Trap HP nickel-charged chelating Sepharose Fast Flow (GE Healthcare)
5-mL column using an AKTA FPLC purification system. The column was washed with TBI
buffer and the enzyme was eluted stepwise with 5, 60, 100 and 500 mM imidazole in TBI buffer.
The enzyme fraction eluted with 100 mM imidazole was loaded onto a PD-10 column (Milli-
pore), which removed imidazole and changed the buffer to storage buffer (200 mM potassium
phosphate, pH 7.4, 5 mM EDTA, 5 mMDTT). Finally, the protein monomer was purified
through gel filtration chromatography using a Superdex 75 10/300 GL column (GE Healthcare)
equilibrated with the storage buffer. In the case of the protein expressed in the E. coli BL21
(DE3) strain, in the absence of chaperones, the TBI and storage buffers contained 0.1% (w/v)
sarkosyl throughout the purification procedure. AKR1B10 and AKR1B1 were expressed and
purified as described previously [23].
Fluorimetric and spectrophotometric assays
NADPH binding was analyzed by quenching of Trp intrinsic fluorescence of 0.5 μM protein,
using a Cary Eclipse (Varian) fluorimeter, in 20 mM sodium phosphate, pH 7.0, at 25°C in a
final volume of 1 mL. The excitation wavelength was 290 nm and the emission wavelength was
monitored at 340 nm. AKR1B10 was used as a control. The dissociation constant (KD) values
were calculated by nonlinear fitting of experimental data, using Grafit 5.0 (Eritacus Software),
to the Morrison equation:
DF ¼ DFmax 
½E þ ½NADPH þ KD 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½E þ ½NADPH þ KDÞ2  4  ½E  ½NADPH
q
2  ½E
The activity towards aldehydes, with the exception of retinaldehydes, was analyzed spectro-
photometrically following the decrease in the absorbance of the cofactor NADPH at 340 nm
(ε340 = 6,220 M
−1cm−1) or at 365 nm in the case of cinnamaldehyde (ε365 = 3,510 M−1cm−1)
[24]. Activities were determined in 100 mM sodium phosphate, pH 7.0, at 25°C, using 0.2 mM
NADPH in 0.2-cm path length cuvettes, with freshly prepared substrate solutions. One unit of
activity is defined as the amount of enzyme required to transform 1 μmol of substrate per min
at 25°C.
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HPLC enzymatic activity assay
Activity assays with retinoids were carried out using an HPLC-based methodology [25]. Briefly,
retinaldehyde isomers were solubilized using glass tubes by a 10-min sonication at molar ratio
1:1 with fatty acid-free bovine serum albumin in 90 mM potassium phosphate, 40 mM potas-
sium chloride, pH 7.4. The actual amount of solubilized retinoid was determined based on the
corresponding molar absorption coefficient in aqueous solutions at the appropriate wave-
length: ε400 = 29,500 M
−1cm−1 for all-trans-retinaldehyde and ε367 = 26,700 M−1cm−1 for 9-
cis-retinaldehyde [25]. For retinol isomers, which were used as standards of the reaction prod-
uct, their concentration was determined in hexane using ε325 = 51,770 M
−1cm−1 for all-trans-
retinol [26] and ε325 = 43,765 M
−1cm−1 for 9-cis-retinol [27]. The reactions were started by
the addition of cofactor and carried out for 15 min at 37°C in a final volume of 0.5 mL. With
the aim to measure the steady-state enzymatic activity, the concentration of enzyme was kept
from 25- to 100-fold lower than that of the substrate for all the enzymatic assays. The reactions
were stopped by the addition of 1 mL of cold methanol and after two rounds of extraction with
hexane, retinoids were analyzed by HPLC as previously described [25]. All retinoid manipula-
tions were performed under dim light.
Determination of kinetic constants and inhibition screening
All compounds tested as inhibitors were dissolved in DMSO and assayed in a final concentra-
tion of 0.1% (v/v) DMSO using 6 mM D,L-glyceraldehyde as a substrate. Kinetic constant and
IC50 (compound concentration that inhibits enzymatic activity by 50%) values were calculated
by fitting the initial rates to the appropriate equation using Grafit 5.0 (Eritacus Software) and
values were given as the mean ± standard error of three experiments. Standard error values
were less than 20% of the mean values.
Homology model and conformational ensembles
The structural model of apo-AKR1B15 was obtained from the AKR1B10 ternary complex crys-
tallographic structure (PDB ID: 1ZUA), used as a template for homology modeling, by run-
ning the SCWRL program [28]. Because of the high sequence identity (92%) between the two
proteins, the approach that keeps invariant the conformation of the conserved residues was
adopted. The flexibility features of both AKR1B10 and AKR1B15 were studied by means of
computer simulations.
The hydrogen atoms were added to the structural model of AKR1B15 as well as to the
AKR1B10 crystal by the pdb2gmx tool of the GROMACS program package [29]. The apo as
well as holo forms of both structures were studied as follows: the all-atom models were energy
minimized employing the Amber99sb-ildn force field [30,31] for the protein, parameters of
Holmberg et al. [32] for the cofactor, and Generalized-Born implicit solvent model with
parameters of Hawkins et al. [33]. The minimized structures were used as the input for the
tCONCOORD algorithm [34], which generates a set of independent conformations based on
geometrical constraints [35]. It was designed to accurately capture the protein flexibility and
the validity of the resulting conformational ensembles has been proven on a variety of proteins,
including also AKR1B1 [34]. By means of tCONCOORD, we generated and analyzed the
ensembles of 2500 conformations, which were subsequently used to calculate root mean square
fluctuations (RMSF) of backbone atoms.
The energy minimized geometries (i.e. the starting ones for conformational sampling) were
evaluated employing PROCHECK [36] and Verify 3D [37], which allow checking their stereo-
chemical quality and calculating the percentage of conformations in favored regions obtained
from the Ramachandran plots.
Retinaldehyde Reductase Activity of Human AKR1B15
PLOSONE | DOI:10.1371/journal.pone.0134506 July 29, 2015 4 / 19
AKR1B15 ternary complexes
Geometries of the ternary complexes were derived from the homology model of holo-
AKR1B15, which was built by superimposition of the apo form and holo-AKR1B10 (PDB ID:
1ZUA), including the cofactor coordinates into apo-AKR1B15. Considering that all-trans-reti-
naldehyde and 9-cis-retinaldehyde are substrates, the distance between the oxygen of retinalde-
hyde and the catalytic residues (i.e. His111 and Tyr49) should be less than 3 Å for productive
catalysis to occur. Under this assumption, the substrates were manually docked into the active
site of holo-AKR1B15. Inhibitors were automatically docked using AutoDock 4.0 [38]. The
inhibitor JF0064 coordinates were obtained from the PDB (PDB ID 4ICC). The target geome-
try was extracted from the energy minimized all-trans-retinaldehyde complex (see below). For
docking, the target was kept rigid, while all the torsional bonds in JF0064, except for the conju-
gated double bonds, were free to move. The docking parameters were the same as described
previously [39].
The hydrogen atoms were added to the ternary complex and the complex was energy mini-
mized by adopting the PM6-D3H4 method [40] combined with the COSMO solvent model
[41]. The residues, with at least one atom within 5 Å from any atom of the cofactor, substrate
or inhibitor, were allowed to move and the rest was kept frozen but included in the Hamilto-
nian calculation. The PM6-D3H4 method, which has been developed to accurately describe
non-covalent interactions in biomolecules, represents a well-established computational tool
[42] and recently it has been used in the study of the inhibition of AKR1B1 [43]. The final pdb
files of holo-AKR1B15 and the ternary complexes were validated with the QMEAN server [44],
with the flag “ignoring the agreement terms”, recommended for proteins known to have the
correct fold. The volume of the active-site pocket was measured by using the POVME algo-
rithm [45], whereas PyMOL (v.1.3; Schrödinger) was used for figure drawing.
Results and Discussion
Expression and purification of recombinant human AKR1B15
We attempted the expression and purification of recombinant AKR1B15 using different E. coli
strains and procedures. In all cases, the protein appeared to be mostly present in the insoluble
fraction of cell lysates. Previously, Salabei et al. [6] had described a successful procedure based
on the use of the anionic detergent sarkosyl (sodium N-lauroylsarcosinate). In our hands and
in the presence of sarkosyl, the amount of soluble protein and the final yield were acceptable
(Fig 1A and 1B). However, AKR1B15 was mainly associated with higher molecular weight
aggregates (Fig 1C), which were found to be enzymatically inactive. Only a small fraction of
AKR1B15 was found to be in an active monomeric form. A minimal concentration of sarkosyl
(0.001%, w/v) was necessary to avoid protein precipitation. Sarkosyl had been described as an
enzyme inhibitor [46], and was confirmed that it inhibited AKR1B15 following a non-competi-
tive model (data not shown). As an alternative procedure for expression, an E. coli BL21(DE3)
strain co-expressing three chaperone systems (DnaK-DnaJ-GrpE, ClpB and GroEL-GroES)
[22] was used. Under these conditions, AKR1B15 was still found to be mainly associated with
the insoluble fraction, but the amount of soluble protein recovered increased significantly (Fig
1A). Peptide mass fingerprint analysis of the soluble protein fraction separated by SDS-PAGE
identified the isolated band as being human AKR1B15 (data not shown). The enzyme was puri-
fied with a final yield of 1 mg protein per liter of culture, when using minimal medium. Analy-
sis by gel filtration chromatography showed a molecular weight of 37 kDa for the purified
protein, suggesting that AKR1B15 was obtained as a monomer (Fig 1C). By analyzing the puri-
fied protein on SDS-PAGE (Fig 1B, lane 2), the major band corresponded to the 37-kDa
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Fig 1. Expression and purification of recombinant human AKR1B15. (A) SDS-PAGE analysis of protein expression, showing that AKR1B15 was
predominantly associated with the insoluble fraction of BL21(DE3) cell lysates. Treatment with 1% (w/v) sarkosyl (Sk) provided a much higher amount of
AKR1B15 in the soluble fraction. In the case of BL21(DE3) pBB540 pBB542 cells, a protein band which is highlighted with a red oval was identified as human
AKR1B15 by Peptide Mass Fingerprinting. Lanes: C, control for the soluble fraction not induced by IPTG; S, soluble fraction; and I, insoluble fraction. (B)
SDS-PAGE analysis of protein purification, showing fractions eluted from the nickel affinity column chromatography using 100 mM imidazole. Lanes: 1,
Protein eluted from the soluble fraction of BL21(DE3) + Sk; and 2, Protein eluted from the soluble fraction of BL21 (DE3) pBB540 pBB542. (C) Elution profile
from the Superdex 75 10/300 GL column chromatography. AKR1B15 purified from soluble fraction of BL21(DE3) + Sk and from soluble fraction of BL21
(DE3) pBB540 pBB542 are shown in grey and black lines, respectively. Major peaks eluting at 7.9 and 11.4 mL correspond to aggregated (132 kDa) and
monomer (37 kDa) protein, respectively.
doi:10.1371/journal.pone.0134506.g001
Retinaldehyde Reductase Activity of Human AKR1B15
PLOSONE | DOI:10.1371/journal.pone.0134506 July 29, 2015 6 / 19
enzyme, with some minor contaminating protein bands. Fluorescence analysis of cofactor
binding allowed us to determine the KD value for NADPH (113 ± 9 nM, Fig 2). The determined
KD value was in the same range with that of AKR1B10 (KD = 92 ± 35 nM).
Enzymatic activity and inhibition studies
It has been recently reported that AKR1B15 catalyzes the reduction of acetoacetyl-CoA and the
carbonyl group at C17 position of sex steroids [16]. Additional results, obtained by using pro-
tein extracts from transfected human COS-7 cells, indicated that AKR1B15 exhibited very
weak activity towards D,L-glyceraldehyde and 4-nitrobenzaldehyde [6], which are typical sub-
strates of AKR enzymes. Our current analysis shows that the purified recombinant enzyme has
broad substrate specificity and displays a significant enzymatic activity towards aliphatic and
aromatic aldehydes and ketones (Table 1). AKR1B15 was active with D,L-glyceraldehyde, which
was used as a substrate in the standard assay. The enzyme reduced 200 mM glucose with a
much lower rate (12 mU/mg) than that exhibited by AKR1B1 (500 mU/mg), precluding the
determination of kinetic constants. In contrast, AKR1B15 displayed a catalytic activity compa-
rable or higher than that of AKR1B1 and AKR1B10 with a variety of physiological or model
aldehydes and ketones of various classes. Among the compounds assayed, medium-chain (i.e.
 6-carbon) aliphatic and aromatic carbonyl compounds were excellent substrates, with Km
values in the low micromolar range. Importantly, AKR1B15 was also active towards retinalde-
hyde isomers (Table 2), which along with acrolein, trans-2-hexenal, 4-hydroxy-2-nonenal and
farnesal may constitute physiological substrates for this enzyme. The 9-cis isomer of retinalde-
hyde was the best substrate based on the catalytic efficiency (kcat/Km) due to a very low Km
value (160 nM) (Table 2), which could be determined by the use of an HPLC-based method
providing higher sensitivity than the spectrophotometric assay. Regarding cofactor specificity,
AKR1B15 was confirmed to be NADPH dependent (i.e. the enzymatic activity using 0.2 mM
NADH was less than 5% of that with NADPH), as reported in [16], and described for most
AKRs. The Km value of AKR1B15 for NADPH (5 μM) is within the same range as those of
AKR1B1 and AKR1B10 (Table 1).
The comparison between AKR1B15 and the other human AKR1B enzymes reveals some
relevant distinct kinetic features (Table 1). In particular, ketones and α-dicarbonyl compounds
were good substrates for AKR1B15, showing higher activity and lower Km values than
AKR1B10 and AKR1B1. The β-dicarbonyl compound, 2,4-pentanedione, was also reduced by
AKR1B15, consistent with the reported activity with acetoacetyl-CoA, which also has two car-
bonyl groups in a β-position [16]. For other substrates, AKR1B15 exhibited lower Km values
than AKR1B10, suggesting that AKR1B15 could play a role in aldehyde detoxification, similar
to what has been suggested for other AKR1B enzymes [47]. AKR1B15 resembles AKR1B10 in
having high activity with retinoids, in contrast to AKR1B1 (Table 2). A distinct feature of
AKR1B15 is that it keeps similar kcat values towards all assayed substrates, including retinoids,
suggesting a common rate-limiting step. In comparison, the kcat values of AKR1B1 with both
retinaldehyde isomers and AKR1B10 with the 9-cis isomer are significantly lower than those
for other substrates. This decrease in kcat values had been interpreted before as a change in the
rate-limiting step (from cofactor dissociation to a slower step) of AKR1B1 and AKR1B10 reac-
tions with these retinoids [23]. This seems not to be the case for AKR1B15. Finally, the higher
specificity of AKR1B15 for the 9-cis isomer is unique for the human AKR1Bs, and it matches
those of AKR1C3 [48], which like AKR1B15 also has bulky Phe residues at positions 299 and
304 in its active site, and chicken AKR [49].
Seven AKR inhibitors were tested against AKR1B15 using D,L-glyceraldehyde as substrate
(Table 3). Among these inhibitors, there are five of the carboxylic acid type (tolrestat,
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epalrestat, oleanolic acid, sulindac and lithocholic acid), one of cyclic imide type (sorbinil) and
one non-classical aldose reductase inhibitor or ARI (JF0064, which has been recently described
by Cousido-Siah et al [15], Fig 3). Tolrestat, JF0064 and sulindac are potent inhibitors of
AKR1B1 as well as of AKR1B10 (with IC50<10 μM for both enzymes). Sorbinil and epalrestat
are more selective against AKR1B1 [50,51], while oleanolic and lithocholic acid are more selec-
tive against AKR1B10 [52]. For AKR1B15, only JF0064 showed a significant inhibition (IC50 =
0.034 ± 0.005 μM, Table 3), much stronger than for AKR1B1 and AKR1B10 [15]. The steroid
lithocholic acid was found to be an inhibitor of AKR1B15, in agreement with the reported
observation that certain steroids are good substrates for this enzyme [16].
Structural model of AKR1B15
With the aim to compare the substrate-binding site of AKR1B15 with that of AKR1B10, and
upon unsuccessful attempts of protein crystallization, a 3D homology model of AKR1B15 was
built (Fig 4A). The SCWRL server was chosen, as it is designed specifically for predicting side-
chain conformations, provided a fixed backbone usually obtained from an experimental struc-
ture. In practical terms, this is the case of AKR1B15, given its 92% sequence identity with
AKR1B10. Model quality was checked by PROCHECK analyses, indicating that most residues
are in the preferred regions (94.8%), whereas residues in allowed regions and outliers are 3.5
and 1.6%, respectively. The compatibility of the atomic model (3D) was checked with its own
amino acid sequence (1D) using Verify 3D analysis. This analysis shows that there is no region
with negative scores, which would otherwise indicate potential problems. In addition, the anal-
ysis using the QMEAN server indicates the reliability of the model, with a QMEAN score of
0.67 out of 1, and with all the Z-scores being consistent with the good quality of the structure.
Thus it may be concluded that this model is suitable for structural studies.
Model analysis
Regarding the cofactor-binding site, AKR1B15 shares with AKR1B10 all residues, except for
Arg22, Met265 and His269 (Fig 5). The change of Lys22 in AKR1B10 to Arg in AKR1B15 may
prevent its interaction with the pyrophosphate bridge of NADP+ but, due to the mobility of the
Arg side chain in solution, its interaction with the cofactor cannot be excluded. Met265 and
His269 keep interactions with the same groups of NADP+ that involve Val265 and Arg269 in
Fig 2. Quenching of AKR1B15 and AKR1B10 fluorescence upon binding of NADPH.Change of the
protein fluorescence intensity (in percentage) upon addition of cofactor is shown. All proteins were used at a
concentration of 0.5 μM in 20 mM sodium phosphate, pH 7.0, at 25°C. Graph symbols: AKR1B15
(diamonds), AKR1B10 (open squares).
doi:10.1371/journal.pone.0134506.g002
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AKR1B10 (i.e. a hydrogen bond between the N atom of Met265 and the 20-phosphate group, a
second hydrogen bond between the Nε of His269 and the 20-phosphate group, and a stacking
interaction of His269 with the adenine ring). Interestingly, a His residue at position 269 and its
interactions have also been described in the rat AKR1B14 X-ray structure [53]. The salt bridge
between the side-chain of Asp217 and Lys263, acting as a safety belt in cofactor binding, and
the stacking interaction of Tyr210 side chain with the nicotinamide ring are also conserved.
Table 1. Kinetic constants of AKR1B15, AKR1B10 and AKR1B1 with aldehydes and ketones.
Substrate AKR1B15 AKR1B10 AKR1B1
Km
(μM)
kcat
(min−1)
kcat/Km
(mM−1min−1)
Km
(μM)
kcat
(min−1)
kcat/Km
(mM−1min−1)
Km
(μM)
kcat
(min−1)
kcat/Km
(mM−1min−1)
Carbohydrate
aldehydes
D,L-glyceraldehyde 880 10.7 12.4 6,000a 35a 6a 50a 31a 660a
Aromatic aldehydes
pyridine-3-aldehyde 2.9 9 3,150 13b 150b 12,000b 10b 61b 6,100b
benzaldehyde <1* 12.1 >12,100 9.7b 104b 11,000b 21b 91b 4,300b
cinnamaldehyde <1* 13.3 >13,300 34.7 240 6,900 31 29 950
Alkanals
hexanal 3.1 7.3 2,300 112b 142b 1,300b 5b 28b 5,600b
Alkenals
acrolein 36 8.8 240 110c 116c 1,070c 884c 11c 12c
trans-2-hexenal 5 11.3 2,200 28b 49b 1,700b 9b 16b 1,800b
4-hydroxy-
2-nonenal
2.2 5.2 2,500 31c 121c 3,900c 716c 50c 70c
citral 1.5 5.5 3,700 4.5 35 7,400 35 68 1,750
farnesal <1* 4.8 >4,800 2.3b 30b 13,000b 37b 27b 700b
Ketones
2-butanone 780 10.5 13.5 LA LA
3-buten-2-one 21.3 8.2 380 LA LA
3-nonen-2-one 1.7 6.76 4,000 LA LA
2-cyclohexen-1-one 365 4.41 12.1 LA LA
α-Dicarbonyls
2,3-butanedione <1* 10.6 >10,600 540d 260d 480d 110d 23d 210d
2,3-hexanedione <1* 9.5 >9,500 51b 79b 1,500b 17b 49b 2,900b
β-Dicarbonyls
2,4-pentanedione 40 2.2 55 58,900 8.6 0.15 8,100 16.7 2.2
3,5-heptanedione 1,300 5.3 3.9 >50,000 - - 12,000 26 2.2
Cofactor
NADPH 5.7 10 2.9e
Enzymatic activity was measured spectrophotometrically. For the determination of the kinetic parameters for NADPH, 3 and 60 mM D,L-glyceraldehyde
was used with AKR1B15 and AKR1B10, respectively. LA, low activity ( 10 mU/mg) was detected at saturating concentration of substrate for AKR1B15;
ND, not determined.
*Because of very low Km value, data are only approximate.
aData from [23].
bData from [66].
cData from [67].
dData from [68].
eData from [69].
doi:10.1371/journal.pone.0134506.t001
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This is consistent with the AKR1B15 cofactor preference for NADP(H) and the low Km value
of AKR1B15 for NADPH.
On the other hand, the active site displays high divergence between AKR1B15 and
AKR1B10. The residue differences between the two proteins are concentrated in loops A and C
which, along with loop B, give shape to the active-site pocket (Fig 4A). Thus, the catalytic resi-
dues (Asp44, Tyr49, Lys78 and His111) and those in loop B are strictly conserved. In contrast,
Ser118, Leu122, Ala131, and Gly133 (in loop A), together with Cys299, Asn300, Val301,
Leu302, Gln303, Ser304, and Tyr310 (in loop C) of AKR1B10 are substituted by Thr118,
Phe122, Met131, Ser133, Phe299, Asp300, Phe301, Lys302, Glu303, Phe304 and Phe310, in
AKR1B15. Noteworthy, residues Phe299, Phe301, Glu303 and Phe304, along with Phe48
(Val48 in AKR1B10), participate in the AKR1B15 active-site pocket, which is thus significantly
smaller (60 Å3 for AKR1B15 versus 279 Å3 for AKR1B10) and more hydrophobic, compared to
the AKR1B10 pocket (Fig 4B and 4C). Some of these substitutions might not only have a conse-
quence on the shape, volume and hydrophobicity of the active site, but also on the flexibility of
the polypeptide chain, which is most relevant in the loop regions. The analysis of
Table 2. Kinetic constants with retinaldehyde isomers.
Substrate and parameter AKR1B15 AKR1B10a AKR1B1a
All-trans-retinaldehyde
Km (μM) 1 ± 0.3 0.6 ± 0.1 1.1 ± 0.1
kcat (min
−1) 5.4 ± 0.5 27 ± 1 0.9 ± 0.1
kcat/Km (mM
−1min−1) 5,300 ± 1,700 45,000 ± 7,600 1,300 ± 160
9-cis-retinaldehyde
Km (μM) 0.16 ± 0.03 0.7 ± 0.1 0.4 ± 0.1
kcat (min
−1) 3.8 ± 0.2 0.9 ± 0.1 0.7 ± 0.2
kcat/Km (mM
−1min−1) 25,600 ± 5,300 1,300 ± 190 1,500 ± 170
Enzymatic activity was measured by using the HPLC-based method.
aData from [23]
doi:10.1371/journal.pone.0134506.t002
Table 3. Inhibitory effect of different compounds on enzymatic activity.
IC50 (μM)
Inhibitor AKR1B15 AKR1B10 AKR1B1
Tolrestat > 100 0.006 0.01a
Sorbinil > 100 9.6b 0.55b
JF0064 0.034 ± 0.005 1.0d 0.3d
Epalrestat > 50 0.33c 0.021c
Oleanolic acid > 100 0.09b 124b
Sulindac >100 0.35c 0.21c
Lithocholic acid 16.3 ± 7.6 0.12d 7.2d
The enzymatic activity assay with inhibitors was performed by using D,L-glyceraldehyde as a substrate. JF0064: 2,2’,3,3’,5,5’,6,6’-octaﬂuoro-4,4’-
biphenyldiol
aData from [70].
bData from [52].
cData from [71].
dData from [66]
doi:10.1371/journal.pone.0134506.t003
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conformational ensembles indicates that AKR1B15 would display less flexible loops A and C
than AKR1B10 (Fig 4D). A detailed analysis of the AKR1B15 model shows van der Waals
interactions between residues from these loops and residues from other protein regions (i.e.
Trp21-Phe299_loopC, Phe48-Phe116_loopA, Phe48-Phe123_loopA, Phe48-Phe301_loopA,
Trp112_loopA-Phe301_loopC, Phe116_loopA-Phe304_loopC, Phe123_loopA-Phe304_loopC,
Met131_loopA-Phe304_loopC and Met131_loopA-Leu307_loopC). Such interactions result in a
hydrophobic cluster (Fig 4E), which likely contributes to the lower flexibility of the AKR1B15
active site.
Docking of substrates and the inhibitor JF0064
As it has been described above, AKR1B15 is active towards retinoids, and thus the binding
mode of all-trans- and 9-cis-retinaldehyde was analyzed. The obtained models were also
Fig 3. Molecular structure of compound JF0064, 2,2’,3,3’,5,5’,6,6’-octafluoro-4,4’-biphenyldiol.
doi:10.1371/journal.pone.0134506.g003
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analyzed with the QMEAN server and displayed similar scores (0.68/1 and 0.69/1, respectively)
as the AKR1B15 holoenzyme model. The analysis showed that both substrates could be placed
with their carbonyl groups at catalytic distance from the hydroxyl group of Tyr49, the Nε of
His111, and the cofactor C4 atom (2.9, 2.9, and 3.2 Å, respectively). The two molecules would
be positioned in a similar manner into a narrow and hydrophobic pocket, establishing contacts
with Trp21, Phe48, Phe123, Trp220, and Phe301 (all-trans-retinaldehyde), and Phe48, Trp220,
Phe299, and Phe301 (9-cis-retinaldehyde) (Fig 6A). A slight rearrangement of loop A and loop
Fig 4. Model of AKR1B15 structure. (A) Side view of the (α/β)8 barrel. In red, the divergent residues between AKR1B15 and AKR1B10. (B) and (C) Active-
site pockets of AKR1B15 and AKR1B10, respectively. The AKR1B15-specific residues are displayed in magenta. NADP+ cofactor is colored in orange. The
surface contour of pockets is shown in grey and orange for AKR1B15 and AKR1B10, respectively. (D) The local conformational changes in holo forms of
AKR1B15 (red line) and AKR1B10 (blue line) derived from computer simulations, as indicated by root mean square fluctuations (RMSF) of backbone atoms.
The residues of loops A, B and C are highlighted by grey background. The difference in RMSF between the two enzymes is displayed as a black line in the
top. (E) AKR1B15 loops A and C indicating potential contacts between different residues are shown as sticks, which may explain the low flexibility of the
protein in this region. Figures have been drawn using PyMOL.
doi:10.1371/journal.pone.0134506.g004
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C (Fig 6A) could allow the establishment of a hydrogen-bond or an electrostatic interaction
between Lys125 and Glu303 (Fig 6B).
The particular AKR1B15 topology brings the cyclohexene ring of all-trans and 9-cis-retinal-
dehyde further away from loops A and C than in AKR1B10 (Fig 6A, 6B and 6C). Thus these
substrates do not interact with the residues that have been described as important for all-trans-
retinaldehyde binding in AKR1B10, and which are in the most external part of the AKR1B10
pocket [23]. Notably, some of these residues are not interacting with the retinoid substrates in
AKR1B15, i.e. Lys125 and Met131 (Ala in AKR1B10) from loop A, Glu303 (Gln in AKR1B10)
and Phe304 (Ser in AKR1B10) from loop C. In AKR1B10, all-trans-retinaldehyde binding
requires a rearrangement of Lys125, not necessary for 9-cis-retinaldehyde, explaining the
higher kcat value towards the former substrate [3]. In the case of AKR1B15, Lys125 is not
involved in the binding of either substrate, being consistent with similar kcat values. The hydro-
phobic pocket in the external region of the active site of the enzyme, where part of the polyene
chain and the cyclohexene ring of the substrate bind, corresponds to the protein region which
shows more rigidity in comparison to AKR1B10 (Fig 4D). Furthermore, this rigidity, likely due
to the presence of the bulky Phe residues (Phe48, Phe299, Phe301 and Phe304), would make
difficult the opening of the so-called “specificity pocket” (Fig 6B and 6C), which has been
described for ARI binding in AKR1B10 and AKR1B1 and which usually accommodates the
hydrophobic moiety of inhibitors [52,54]. This feature could have important functional conse-
quences. For instance, it could explain the different substrate specificity and inhibitor selectiv-
ity of AKR1B15, since flexibility has been well established in connection with the active-site
accessibility, and substrate and ligand binding [55].
The compound JF0064 is the only ARI found to significantly inhibit AKR1B15, probably
due to the reduced volume of the active-site cleft and to the difficulty in opening the “specificity
pocket”. In order to analyze JF0064 binding, a docking simulation along with energy
Fig 5. Comparison of the cofactor-binding site between the AKR1B15model (A) and the AKR1B10 crystal structure (B). Interactions of Met265 and
His269 with NADP+ in AKR1B15 are similar to those of Val265 and Arg269 in AKR1B10 (black dotted lines). His269 forms a π-stacking interaction with the
adenine ring of the cofactor. The substitution of Lys22 by Arg in AKR1B15 prevents its interaction with the pyrophosphate bridge of NADP+. The salt bridge
between Asp217 and Lys263 (red dotted line), acting as a safety belt in the coenzyme binding, and the π-stacking interaction of Tyr210 with the cofactor
nicotinamide ring are conserved between the two AKRs. Carbon atoms of the cofactor are shown in green, whereas those of the enzyme are colored grey.
Figures have been drawn using PyMOL.
doi:10.1371/journal.pone.0134506.g005
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minimization was performed. The model was again validated by using the QMEAN server and
displayed a similar, though slightly better score than the rest of the AKR1B15 models (0.72/1).
The Z-score (which is tending from negative digits to 0 when approximating to experimentally
determined structures) of the AKR1B15-NADP+-JF0064 model (−0.92) is comparatively
Fig 6. Molecular docking of substrates or inhibitors to the active-site pocket of AKR1B15. (A) Residues implicated in binding all-trans- and 9-cis-
retinaldehyde are displayed in light and dark grey sticks; while the substrates are shown in light and dark blue, respectively. The residues found in the most
external part of all-trans-retinaldehyde binding channel in AKR1B10 are highlighted in yellow. The energy minimized apo-conformation is displayed in
magenta cartoon. (B) and (C) Side view of the surface contour of the active-site pocket, depicted in grey and orange for AKR1B15 and AKR1B10,
respectively, to show the inhibitor “specificity pocket”. A thick grey curved line indicates the “specificity pocket” in AKR1B10. As it is shown, this pocket may
not be opened in AKR1B15, likely due to the presence of bulky Phe residues. (D) The inhibitor JF0064 (PDB ID 4ICC) bound to AKR1B15 is displayed as
sticks with C atoms in magenta, while residues interacting with the inhibitor are shown as sticks with C atoms in grey. (E) Steric hindrance preventing tolrestat
(in blue) and sorbinil (in orange) from binding to the active site of AKR1B15. For this analysis, the AKR1B15 structure model was superimposed with the
AKR1B10 crystallographic structures with tolrestat (PDB ID 1ZUA) and sorbinil (PDB ID 4GA8). NADP+ is colored in orange. Figures have been drawn using
PyMOL.
doi:10.1371/journal.pone.0134506.g006
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improved with respect to the AKR1B15 holoenzyme model (−1.64). All-trans- and 9-cis-reti-
naldehyde complexes show intermediate values of −1.51 and −1.35, respectively.
The conformation of the AKR1B15-NADP+-JF0064 complex corresponding to the energy
minimum is displayed in Fig 6D. Binding would occur through van der Waals interactions
with a large number of hydrophobic residues, and by establishing hydrogen bonds with cata-
lytic residues (Tyr49 and His111) and Glu303. As it has been described above for substrates,
the binding of the inhibitor also induced the same rearrangement of loop A and loop C, allow-
ing for the interaction between Lys125 and Glu303. The other tested compounds did not
inhibit AKR1B15 likely because of steric hindrance (e.g. Phe301 and Phe48 may clash against
sorbinil, and Phe304, along with the fact that the “specificity pocket” could not be opened, may
prevent tolrestat from binding) (Fig 6C and 6E).
Physiological significance
The kcat/Km value of AKR1B15 for 9-cis-retinaldehyde (25,600 mM−1min−1) is the highest
among all the substrates checked so far, including the steroids and 3-keto-acyl-CoAs analyzed
by Weber et al. [16], although these authors used different conditions for enzyme purification
and kinetic studies. This is reminiscent of what has been observed for other members of the
AKR superfamily, such as AKR1C3, which displays a high kcat/Km value for 9-cis-retinalde-
hyde but it is also active against steroids and prostaglandins [48]. Observations of dual sub-
strate specificity have also been made for members of the short-chain dehydrogenase/reductase
superfamily [56]. Thus, it is conceivable that AKR1B15 and some of these enzymes have a mul-
tifunctional role in the pre-receptor regulation of hormonal signaling pathways. The AKR1B15
specificity for the 9-cis isomer may suggest a major role in the control of RAR and RXR medi-
ated signaling, but we cannot exclude other physiological functions. Regarding the reported
localization of AKR1B15 in mitochondria, there is increasing evidence that retinoid metabo-
lism takes place in different subcellular compartments [57,58], mitochondria being one of
them. Carotenoids and their aldehyde metabolites can be generated by the asymmetric cleavage
of β-carotene by β-carotene-9’,10’-oxygenase (BCO2), which is associated with the inner mito-
chondrial membrane [59]. Therefore, a putative physiological role of AKR1B15 in retinoid
metabolism is compatible with its mitochondrial localization. The presence in mitochondria of
other retinaldehyde reductases, such as RDH13 [57], gives further support to this notion. In
addition, RDH10, an enzyme involved in retinoic acid synthesis, shifts between mitochondria
associated membranes and lipid droplets during retinyl ester biosynthesis, similarly to cellular
retinol-binding protein type 1 [60]. Retinol has also been pinpointed as a modulator of energy
homeostasis in mitochondria by regulating oxidative phosphorylation [61]. An additional role
of AKR1B15 in metabolizing lipid peroxidation products and alkenals in mitochondria cannot
be ruled out [62,63].
Conclusions
Despite its high sequence identity with AKR1B10, AKR1B15 appears to be an enzyme with a
unique substrate specificity and narrower inhibitor selectivity. AKR1B15 displays distinct
kinetic features with ketones, α-dicarbonyl compounds and is among the best 9-cis-retinalde-
hyde reductases within the AKR superfamily. Some of the most potent inhibitors of AKR1B1
and AKR1B10 did not inhibit AKR1B15. Amino acid substitutions clustered in residues located
in loops A and C result in a smaller, more hydrophobic and more rigid active-site pocket of
AKR1B15 as compared to that of AKR1B10. The structural model of AKR1B15 provides a
powerful tool for the virtual screening of substrates and inhibitors for this enzyme. The distinct
topology of the AKR1B15 fold should facilitate the design of more selective inhibitors, as it has
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been shown for other enzyme pairs with high sequence similarity [64,65]. Finally, the finding
of all-trans- and 9-cis-retinaldehyde as substrates for AKR1B15 adds further complexity to the
enzymatic pathways of retinoid transformations and their cross-talk with other hormonal sig-
naling pathways, such as that of steroids. This opens a research line to elucidate the physiologi-
cal contribution of this novel human retinaldehyde reductase.
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